16 July 2018 - - Cambridge, Massachusetts-based immune system biotech company Compass Therapeutics has closed the final USD 49m of its USD 132m series A financing, the company said.
This financing will enable the company to advance its therapeutic platform into the clinic.
Compass is pioneering a new approach to identifying antibody drug candidates that engage all targets in the biologically complex human immune synapse, with an initial focus on T cells, NK cells, and macrophages.
The company's antibody discovery and bispecific engineering platforms enable the rapid identification of therapeutic candidates that engage with a broad range of epitopes on every target.
Specifically, StitchMabs, a novel and proprietary high-throughput bispecific screening platform, enables the rapid identification of synergistic bispecific activity.
The antibody discovery platform enables drugging of two new targets per month, and therapeutic candidates are generated in less than two months from antigen to candidate set. The integrated R and D approach has generated therapeutic candidates for more than 30 targets in cancer, inflammation, and autoimmune disease.
Compass currently has over 15 antibody, antibody combination, and bispecific programs advancing through preclinical development, targeting multiple pathways of significance for the immune system. Compass currently has approximately 70 full-time employees.